SEC Form 4 · accession 0000899243-19-005307
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel W Muehl
Officer — See Remarks
Period of report
Feb 27, 2019
Accepted (ET)
Feb 28, 2019 · 6:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 27, 2019 | M | 547 | — | A | 6,211 | D | |
| Common StockF2 | Feb 27, 2019 | S | 266 | $25.90 | D | 5,945 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F1 | — | Feb 27, 2019 | M | 547 | D | — | — | Common Stock | 547 | 3,281 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- F2Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
- F3On August 25, 2016, the reporting person was granted 8,750 Restricted Stock Units. 25% of such Restricted Stock Units vested on August 25, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Remarks
Executive Vice President of Finance, Principal Financial Officer and Principal Accounting Officer